h指数及其衍生指标评估兽用疫苗领域单篇专利的适用性探索

随着禽流感、非洲猪瘟等疾病的出现,兽用疫苗的开发研制成为了动物防疫体系建设的重要一环,同时兽用疫苗领域国际竞争日益激烈,直接影响到我国相关企业的生存和发展,因此国家必须加强对兽用疫苗领域专利质量和专利保护的重视.本文以计量学中的h指数及其衍生指标为对象,研究其与传统专利价值评估指标的关系,通过相关性分析来筛选评估兽用疫苗领域高价值专利的指标.结果表明:h指数、g指数和hg指数这三个指标,与传统专利价值评估指标相关性强,且计算简便,相对于传统指标,能够快速准确地对兽用疫苗领域专利价值进行预估.     

商品化猪丹毒疫苗分类及特点

文章介绍了5种商品化猪丹毒疫苗的种类、毒株组成、抗原含量及相应免疫程序,为了解各种类型的猪丹毒商品化疫苗提供参考。     

Comparison of flagellin and an oil-emulsion adjuvant in inactivated Newcastle disease vaccine in stimulation of immunogenic parameters

The present study was designed to investigate the potential application of native (N) and recombinant (truncated modified [tmFliC] and full-length [flFliC]) flagellin proteins along with inactivated Newcastle disease virus (NDV). Fifty six SPF chickens were immunized twice with PBS (control), inactivated NDV (Ag), inactivated NDV/flFliC (AgF), inactivated NDV/tmFliC (AgT), inactivated NDV/N (AgN), commercial vaccine containing Montanide (Vac) and Vac/N (VacN), with a two-week interval. Blood was collected weekly and spleens were harvested after chickens were sacrificed. Interleukin-6 (IL-6) and tumor necrotic factor-α (TNF-α) gene expression in peripheral blood mononuclear cells were analyzed by Real-Time PCR. Antibody response was assessed by haemagglutination inhibition (HI). Cellular activity was quantified by MTT assay. Results showed that the most IL-6 and TNF-α gene expression was observed in AgF group (P < 0.01). The lowest gene expression among vaccinated groups was observed in Ag group for IL-6 and Ag and Vac group for TNF-α. The highest HI titer was observed in Vac, VacN, AgF and AgT groups. The AgF group showed the highest cellular activity (P < 0.01). In conclusion, flagellin-adjuvanted groups showed a pro-inflammatory effect and acted similarly to or better than the Vac group. Hence, flagellin can be proposed as a potential adjuvant for ND vaccine.     

Immunization of BALB/c mice with Brucella abortus 2308ΔwbkA confers protection against wild-type infection

Brucellosis is a zoonotic disease that causes animal and human diseases. Vaccination is a major measure for prevention of brucellosis, but it is currently not possible to distinguish vaccinated animals from those that have been naturally infected. Therefore, in this study, we constructed the Brucella (B.) abortus 2380 wbkA mutant (2308ΔwbkA) and evaluated its virulence. The survival of 2308ΔwbkA was attenuated in murine macrophage (RAW 264.7) and BALB/c mice, and it induced high protective immunity in mice. The wbkA mutant elicited an anti-Brucella-specific immunoglobulin G response and induced the secretion of gamma interferon. Antibodies to 2308ΔwbkA could be detected in sera from mice, implying the potential for use of this protein as a diagnostic antigen. The WbkA antigen would allow serological differentiation between infected and vaccinated animals. These results suggest that 2308ΔwbkA is a potential attenuated vaccine against 16M. This vaccine will be further evaluated in sheep.     

狂犬病灭活疫苗CVS-11株对牛的免疫效果

野生狐和貉狂犬病流行于新疆、内蒙古和黑龙江地区,是当地牛、羊和骆驼等家畜狂犬病的主要传染源。在国内尚无野生动物口服疫苗的前提下,对家畜进行狂犬病灭活疫苗接种,具有重要的公共卫生学意义。本研究利用国产犬用狂犬病灭活疫苗(CVS-11株)对牛进行了免疫效果和安全性评价。以不同剂量疫苗肌内注射免疫成年牛350头,通过比较免疫后狂犬病病毒中和抗体水平和持续期,确定犬用狂犬病灭活疫苗(CVS-11株)在牛的最佳免疫剂量为1次性注射2剂量疫苗,免疫持续期为1年。结果表明,犬用狂犬病灭活疫苗(CVS-11株)免疫牛时,具有较高的免疫原性和安全性,适用于牛等大型动物的狂犬病注射免疫。     

膜分离法纯化浓缩的猪细小病毒灭活疫苗效果研究

为了研究纯化浓缩的猪细小病毒灭活疫苗的免疫效果,应用微滤/超滤管式陶瓷膜分离系统对猪细小病毒细胞收获液进行纯化浓缩,使浓缩液病毒平均含量由10~(4.7)TCID_(50)/mL提高到10~(6.5)TCID_(50)/mL;将纯化浓缩的病毒液经检验合格后,进行甲醛灭活,与注射用矿物白油佐剂制成油包水灭活疫苗;按照猪细小病毒灭活疫苗的质量标准,对制备的灭活疫苗进行检验与免疫效果试验。结果显示:纯化浓缩的猪细小病毒液杂蛋白去除率平均达到71.6%左右;制备的三组灭活疫苗检验均合格;免疫至63 d时,免疫猪体内抗猪细小病毒抗体(HI)水平分别为:纯化浓缩的灭活疫苗平均高达9.62 log_2稀释倍数,常规疫苗平均为8.78log_2稀释倍数,差异显著(P0.05)。试验表明:疫苗病毒细胞收获液进行膜纯化技术处理后,免疫效果显著优于未经纯化的常规灭活疫苗。     

寄生虫半胱氨酸蛋白酶核酸疫苗的研究进展与应用前景

就寄生虫半胱氨酸蛋白酶的一些生理生化与免疫学性质进行了概括,阐述了该酶与宿主免疫应答之间的作用关系,证明了该酶具有作为研制高效核酸疫苗的条件,同时综述了寄生虫半胱氨酸蛋白酶核酸疫苗的发展以及应用前景。     

猪繁殖与呼吸综合征疫苗的研究进展

猪繁殖与呼吸综合征(PRRS)是由猪繁殖与呼吸综合征病毒(PRRSV)引起的严重危害世界养猪业的一种传染病,该病可造成猪的繁殖障碍、呼吸系统病症与生长受阻。本文着眼于PRRSV疫苗的免疫原性、保护效力和安全性,涉及市场上现有的商品化疫苗与已报道的处于试验阶段的相关疫苗研究成果,以期为PRRSV的防控与疫苗研发提供有益的参考。     

Recurrent Temporary Paralysis Reported After Human Rabies Post‐Exposure Prophylaxis

Adverse events can occur after rabies post‐exposure prophylaxis (PEP), and linkage to causality is often difficult to determine. We report a case of recurrent temporary paralysis that began immediately after the initiation of rabies PEP in a man exposed to a bat. The recurrent temporary paralysis first occurred in the patient after his initial dose and then again after day 3 of his rabies PEP. The PEP was terminated prior to a serologic response. The patient continued to experience numerous discrete episodes of temporary paralysis for over two years.     

The protoxin Cry1Ac of Bacillus thuringiensis improves the protection conferred by intranasal immunization with Brucella abortus RB51 in a mouse model

Brucellosis is a zoonotic disease affecting many people and animals worldwide. Preventing this infection requires improving vaccination strategies. The protoxin Cry1Ac of Bacillus thuringiensis is an adjuvant that, in addition to increasing the immunogenicity of different antigens, has shown to be protective in different models of parasitic infections. The objective of the present study was to test whether the intranasal co-administration of pCry1Ac with the RB51 vaccine strain of Brucella abortus confers protection against an intranasal challenge with the virulent strain B. abortus 2308 in BALB/c mice. The results showed that co-administration of pCry1Ac and RB51, increased the immunoprotection conferred by the vaccine as evidenced by the following: (1) decrease of the splenic bacterial load when challenged intranasally with the virulent strain; (2) greater in vivo cytotoxic activity in response to the transference of previously infected cells; (3) further proliferation of cytotoxic TCD8+ cells in response to stimulation with heat-inactivated bacteria; (4) increased production of TNF-α and IFN-γ; and (5) significant IgG2a response. These results indicate that the use of the Cry1Ac protein as a mucosal adjuvant via the intranasal route can be a promising alternative for improving current RB51 vaccine against brucellosis.